Correction  by unknown
CORRECTION
For the article “Protected carotid stenting in high surgical risk patients: The ARCHeR results”, published in J Vasc
Surg 2006; 44:258-68, Dr I. Fourneau was incorrectly stated as the investigator for the Leuven, Belgium site. Geert
Maleux, MD, was the principal investigator.
CORRECTION
For the article “Do device characteristics impact outcome in carotid artery stenting?” published in J Vasc Surg
2006;44:725-30, the first line in Table III contained an error. The line should read 523 (74.6) not 23 (74.6). The
corrected table appears below.
Type Name N (%)
Closed cell Carotid Wallstent (Boston Scientific Corp, Natick, Mass, USA) 523 (74.6%)
X-act (Abbott Vascular Devices, Redwood City, Calif, USA) 23 (3.3%)
NexStent (Endotex, Cupertino, Calif, USA) 3 (0.4%)
Open cell Precise (Cordis, Miami Lakes, Fla, USA) 70 (10.0%)
Zilver (William Cook Europe, Bjaeverkov, Denmark) 37 (5.3%)
Protégé (ev3, Plymouth, Minn, USA) 31 (4.4%)
Memotherm (Bard, Karlsruhe, Germany) 3 (0.4%)
Exponent (Medtronic Vascular, Santa Rosa, Calif, USA) 3 (0.4%)
Sinus Superflex (Optimed, Ettlingen, Germany) 1 (0.1%)226
